BACKGROUND: Tricuspid regurgitation is common in patients with advanced heart failure. The ideal operative strategy for managing tricuspid valve regurgitation (TR) in patients undergoing left ventricular assist device (LVAD) implantation is unclear. This study was designed to evaluate the effect on outcomes of concomitant tricuspid valve repair (TVR) for moderate to severe (3(+)/4(+)) TR at the time of LVAD implantation. METHODS: Patients with >3(+) TR who underwent LVAD implantation from 2005 to 2009 were retrospectively evaluated. Pre-, intra- and post-operative data, including hemodynamics, inotrope requirements and end-organ function parameters, were considered. Outcomes of patients receiving TVR were compared with those who did not receive TVR (NTVR). RESULTS: Seventy-two LVADs were implanted during the study period. Forty-two (58%) patients had ≥ 3(+) TR prior to LVAD implantation. Eight patients underwent TVR and 34 patients did not undergo TVR (NTVR). There were no significant differences in baseline characteristics or severity of TR between the two groups. The TVR group had a longer cardiopulmonary bypass time (p < 0.01) and required more blood products (p < 0.05). Higher post-operative creatinine and blood urea nitrogen (BUN) values were noted in the TVR group. One patient in the TVR group and 3 patients in the NTVR group required right-sided mechanical assistance (p = 0.6). There was no significant difference in short- or long-term mortality between the two groups. CONCLUSIONS: TVR for ≥ 3(+) TR prolonged operative time and showed similar outcomes compared with LVAD implantation alone. A benefit of performing TVR was not demonstrated. As such, TVR may not be necessary at the time of LVAD implantation.
BACKGROUND:Tricuspid regurgitation is common in patients with advanced heart failure. The ideal operative strategy for managing tricuspid valve regurgitation (TR) in patients undergoing left ventricular assist device (LVAD) implantation is unclear. This study was designed to evaluate the effect on outcomes of concomitant tricuspid valve repair (TVR) for moderate to severe (3(+)/4(+)) TR at the time of LVAD implantation. METHODS:Patients with >3(+) TR who underwent LVAD implantation from 2005 to 2009 were retrospectively evaluated. Pre-, intra- and post-operative data, including hemodynamics, inotrope requirements and end-organ function parameters, were considered. Outcomes of patients receiving TVR were compared with those who did not receive TVR (NTVR). RESULTS: Seventy-two LVADs were implanted during the study period. Forty-two (58%) patients had ≥ 3(+) TR prior to LVAD implantation. Eight patients underwent TVR and 34 patients did not undergo TVR (NTVR). There were no significant differences in baseline characteristics or severity of TR between the two groups. The TVR group had a longer cardiopulmonary bypass time (p < 0.01) and required more blood products (p < 0.05). Higher post-operative creatinine and blood ureanitrogen (BUN) values were noted in the TVR group. One patient in the TVR group and 3 patients in the NTVR group required right-sided mechanical assistance (p = 0.6). There was no significant difference in short- or long-term mortality between the two groups. CONCLUSIONS:TVR for ≥ 3(+) TR prolonged operative time and showed similar outcomes compared with LVAD implantation alone. A benefit of performing TVR was not demonstrated. As such, TVR may not be necessary at the time of LVAD implantation.
Authors: Pavan Atluri; Alexander S Fairman; John W MacArthur; Andrew B Goldstone; Jeffrey E Cohen; Jessica L Howard; Christyna M Zalewski; Yasuhiro Shudo; Y Joseph Woo Journal: J Card Surg Date: 2013-09-30 Impact factor: 1.620
Authors: Robert J Brewer; Rafael Cabrera; Mazen El-Atrache; Amna Zafar; Tara N Hrobowski; Hassan M Nemeh; Yelena Selektor; Gaetano Paone; Celeste T Williams; Mauricio Velez; Cristina Tita; Jeffrey A Morgan; David E Lanfear Journal: Int J Artif Organs Date: 2014-11-29 Impact factor: 1.595
Authors: Shuichi Kitada; Tomoko S Kato; Sunu S Thomas; Suzanne D Conwell; Cesare Russo; Marco R Di Tullio; Maryjane Farr; P Christian Schulze; Nir Uriel; Ulrich P Jorde; Hiroo Takayama; Yoshifumi Naka; Shunichi Homma; Donna M Mancini Journal: J Heart Lung Transplant Date: 2013-07-11 Impact factor: 10.247
Authors: Konstantin Zhigalov; Marcin Szczechowicz; Ahmed Mashhour; Bakitbek K Kadyraliev; Sabreen Mkalaluh; Jerry Easo; Juergen Ennker; Harald C Eichstaedt; Alexander Weymann Journal: J Thorac Dis Date: 2019-04 Impact factor: 2.895
Authors: Claudio J R Gomez Hamacher; Carolin Torregroza; Najla Sadat; Daniel Scheiber; Jil-Cathrin von der Beek; Ralf Westenfeld; Ivonne Jeanette Knorr; Martin Sager; Artur Lichtenberg; Diyar Saeed Journal: JTCVS Open Date: 2020-09-24
Authors: Johanna Mulzer; Hristo Krastev; Christoph Hoermandinger; Alexander Meyer; Thomas Haese; Julia Stein; Marcus Müller; Felix Schoenrath; Christoph Knosalla; Christoph Starck; Volkmar Falk; Evgenij Potapov; Jan Knierim Journal: Ann Cardiothorac Surg Date: 2021-05